Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.
Looking for a particular AlveoliX employee's phone or email?
The AlveoliX annual revenue was $3 million in 2026.
Andreas Hugi is the CTO of AlveoliX.
13 people are employed at AlveoliX.
AlveoliX is based in Bern, Bern.
The NAICS codes for AlveoliX are [541713, 541, 54171, 5417, 54].
The SIC codes for AlveoliX are [873, 87].